Document:

Exhibit 4.2 to SB-2

THE SECURITIES REPRESENTED BY THIS WARRANT HAVE BEEN ACQUIRED FOR INVESTMENT AND
HAVE NOT BEEN  REGISTERED  UNDER THE  SECURITIES  ACT OF 1933, AS AMENDED ("1933
ACT")  OR ANY  STATE  SECURITIES  LAWS.  SUCH  SECURITIES  MAY  NOT BE  SOLD  OR
TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR AN EXEMPTION  THEREFROM UNDER
THE 1933 ACT AND ANY APPLICABLE STATE SECURITIES LAWS.

                       CLASS B WARRANT TO PURCHASE SHARES
                                 OF THE STOCK OF
                            IMPLANTABLE VISION, INC.
                  (Void after Expiration Date - March 31, 2007)

                           Issue Date: ________, 2006

         This  certifies  that _______ or his  successors or assigns  ("Holder")
shall be entitled to purchase from Implantable Vision,  Inc., a Utah corporation
("Company"), having its principal place of business at ________________________,
_______  fully paid and  non-assessable  shares of the  Company's  common stock,
("Common  Stock"),  at a price per share equal to the Exercise Price (as defined
below).

         This Class B Warrant is being  issued in  connection  with an  offering
("Offering")  of units  consisting  of  Series  A  Convertible  Preferred  Stock
Convertible  into  Common  Stock and Class A and Class B  Warrants  to  purchase
Common  Stock(the  "Units").  The Offering is being made only to  Investors  who
qualify  as  "accredited  investors"  as such  term is  defined  in Rule  501 of
Regulation  D under the  Securities  Act of 1933,  as amended  (the  "Securities
Act").  Capitalized  terms used herein and not otherwise  defined shall have the
respective meanings set forth in the Purchase Agreement.

         The  initial  exercise  price  (the  "Exercise  Price") of this Class B
Warrant  will be  equal to $5.00  per  share,  subject  to  adjustment  upon the
occurrence of the events described in Section 2 of this Class B Warrant.

         This Class B Warrant shall be  exercisable  into shares of Common Stock
at any time, or from time-to-time, up to and including 5:00 p.m. (New York time)
on March 31, 2007 ("Expiration Date"), provided,  however, if such date is not a
business day, then on the business day  immediately  following such date).  This
Class B Warrant is  exercisable  in whole or in part upon the  surrender  to the
Company at its  principal  place of business  (or at such other  location as the
Company  may  advise  the Holder in  writing)  of this Class B Warrant  properly
endorsed with a form of subscription in  substantially  the form attached hereto
duly filled in and signed and upon payment in cash or by check of the  aggregate
Exercise  Price for the number of shares for which this Class B Warrant is being
exercised as determined in accordance with the provisions hereof.
<PAGE>

1. EXERCISE; ISSUANCE OF CERTIFICATES; PAYMENT FOR SHARES.

     1.1 GENERAL.  This Class B Warrant is  exercisable  in full, or in part for
10,000 or more shares,  in  increments  of 10,000  shares,  except for the final
exercise which may be for the  remainder,  at the option of the Holder of record
at any time or from  time,  to time,  up to the  Expiration  Date for all of the
shares  of  Common  Stock  (but  not for a  fraction  of a share)  which  may be
purchased hereunder. In the case of the exercise of less than all of the Class B
Warrants  represented  hereby,  the  Company  shall  cancel this Class B Warrant
Certificate  upon the surrender hereof and shall execute and deliver a new Class
B Warrant  Certificate  or Class B Warrant  Certificates  of like  tenor for the
balance of such Class B Warrants.  The Company  agrees that the shares of Common
Stock  purchased under this Class B Warrant shall be and are deemed to be issued
to the  Holder  hereof  as the  record  owner of such  shares as of the close of
business on the date on which the exercise notice (attached hereto as Schedule A
or B) is delivered to the Company via facsimile; provided, however, that in such
case this Class B Warrant shall be  surrendered  to the Company within three (3)
business  days.  Certificates  for the  shares  of  Common  Stock so  purchased,
together  with any other  securities or property to which the Holder is entitled
upon such  exercise,  shall be  delivered  to the  Holder by the  Company at the
Company's expense within a reasonable time after the rights  represented by this
Class B Warrant have been so exercised,  and in any event, within three business
days of such exercise and delivery of the Exercise Price.  The Company shall, no
later than the close of business on the first business day following the date on
which the Company receives the exercise notice by facsimile  transmission  issue
and deliver to the Company's  Transfer Agent  irrevocable  instructions to issue
and deliver or cause to be delivered to such Holder the number of Warrant Shares
exercised  within two business days  thereafter  by either  express mail or hand
delivery.   Each  Common  Stock  certificate  so  delivered  shall  be  in  such
denominations of 10,000 or more shares of Common Stock, in increments of 10,000,
as may be  requested  by the  Holder  hereof  and  shall  be  registered  on the
Company's books in the name  designated by such Holder,  provided that no Holder
of this Class B Warrant  shall be  permitted  to  exercise  any  warrants to the
extent that such exercise would cause any Holder to be the  beneficial  owner of
more than 4.999% of the then  outstanding  Company's Common Stock, at that given
time (as determined in accordance with Section 13(d) of the Securities  Exchange
Act of 1934, as amended, and the rules thereunder). This limitation shall not be
deemed to prevent any Holder from  acquiring more than an aggregate of 4.999% of
the Common Stock, so long as such Holder does not beneficially  own, or have the
right to  beneficially  more than 4.999% of the  Company's  Common  Stock at any
given time. The limitations contained herein shall cease to apply upon sixty-one
(61) days' prior written notice from the Holder to the Company.

     1.2 EXERCISE FOR CASH.  This Class B Warrant may be exercised,  in whole at
any time or in part from time to time,  commencing  on the date hereof and prior
to the Expiration Date, by the Holder by the facsimile  delivery of the exercise
notice, as attached hereto, on the date of the exercise and by surrender of this
Class B Warrant  within  three (3)  business  days from the  exercise day at the
address set forth hereof, together with proper payment of the aggregate Exercise

<PAGE>

Price  payable  hereunder  for the Class B Warrant  Shares  ("Aggregate  Warrant
Price"),  or the proportionate part thereof if this Class B Warrant is exercised
in part.  Payment for the Class B Warrant Shares shall be made by wire, or check
payable to the order of the  Company.  If this Class B Warrant is  exercised  in
part, this Class B Warrant must be exercised for a number of whole shares of the
Common  Stock,  and the  Holder  is  entitled  to  receive a new Class B Warrant
covering the Class B Warrant  Shares which have not been  exercised  and setting
forth the  proportionate  part of the Aggregate Warrant Price applicable to such
Class B Warrant Shares.  Upon such surrender of this Class B Warrant the Company
will (a) issue a certificate or  certificates  in the name of the Holder for the
largest  number of whole shares of the Common Stock to which the Holder shall be
entitled and (b) deliver the other securities and properties receivable upon the
exercise  of this Class B Warrant,  or the  proportionate  part  thereof if this
Class B Warrant is exercised in part, pursuant to the provisions of this Class B
Warrant.

     1.3 SHARES TO BE FULLY PAID;  RESERVATION OF SHARES.  The Company covenants
and agrees that all shares of Common Stock which may be issued upon the exercise
of the rights  represented by this Class B Warrant will, upon issuance,  be duly
authorized,  validly  issued,  fully  paid and  nonassessable  and free from all
preemptive  rights of any shareholder  and free of all taxes,  liens and charges
with respect to the issue  thereof.  The Company  further  covenants  and agrees
that,  during the period  within  which the rights  represented  by this Class B
Warrant may be  exercised,  the Company  will at all times have  authorized  and
reserved, for the purpose of issue or transfer upon exercise of the subscription
rights  evidenced  by this Class B  Warrant,  a  sufficient  number of shares of
authorized  but unissued  Common Stock,  when and as required to provide for the
exercise of the rights  represented  by this Class B Warrant.  The Company  will
take all such  action as may be  necessary  to assure that such shares of Common
Stock may be issued as provided  herein without  violation of any applicable law
or regulation,  or of any requirements of any domestic  securities exchange upon
which the Common Stock or other  securities  may be listed;  provided,  however,
that the Company shall not be required to effect a registration under federal or
state  securities  laws with respect to such exercise  other than as required by
the Registration  Rights  Agreement.  The Company will not take any action which
would  result in any  adjustment  of the  Exercise  Price if the total number of

<PAGE>

shares  of  Common  Stock  issuable  after  such  action  upon  exercise  of all
outstanding warrants,  together with all shares of Common Stock then outstanding
and all shares of Common Stock then  issuable  upon  exercise of all options and
upon the conversion of all convertible securities then outstanding, would exceed
the total  number of shares of Common  Stock then  authorized  by the  Company's
Articles of Incorporation ("Company Charter").

     1.4 BUY-IN.  In addition to any other rights available to a Holder,  if the
Company fails to deliver to the Holder a certificate representing Warrant Shares
by the third Trading Day after the date on which delivery of such certificate is
required  by this  Warrant,  and if after  such  third  Trading  Day the  Holder
purchases (in an open market transaction or otherwise) shares of Common Stock to
deliver in satisfaction of a sale by the Holder on or after the Exercise Date of
the Warrant  Shares that the Holder  anticipated  receiving  from the Company (a
"Buy-In"),  then the Company shall, within three Trading Days after the Holder's
request and in the Holder's discretion,  either (i) pay cash to the Holder in an
amount  equal  to  the  Holder's  total  purchase  price  (including   brokerage
commissions,  if any) for the shares of Common Stock so  purchased  (the "Buy-In
Price"),  at which point the Company's  obligation  to deliver such  certificate
(and to issue such Common Stock) shall  terminate,  or (ii)  promptly  honor its
obligation to deliver to the Holder a certificate or  certificates  representing
such  Common  Stock and pay cash to the Holder in an amount  equal to the excess
(if any) of the Buy-In  Price over the  product of (A) such  number of shares of
Common  Stock,  times (B) the Closing Price on the date of the event giving rise
to the Company's  obligation to deliver such  certificate.  Notwithstanding  the
foregoing,  the Company shall have no liability  under this  subsection  for the
Buy-In Price if it has compiled with the  requirements  of subsection  1.1 above
and notwithstanding it using its best efforts to have its transfer agent deliver
the Warrant  Shares to the Holders  within  three  trading  days of the Holder's
request such Warrant Shares are not delivered on a timely basis.

2.  DETERMINATION  OR  ADJUSTMENT  OF EXERCISE  PRICE AND NUMBER OF SHARES.  The
Exercise  Price and the number of shares  purchasable  upon the exercise of this
Class B  Warrant  shall be  subject  to  adjustment  from  time to time upon the
occurrence of certain events  described in this Section 2. Upon each  adjustment
of the Exercise  Price,  the Holder of this Class B Warrant shall  thereafter be
entitled to purchase, at the Exercise Price resulting from such adjustment,  the
number  of  shares   obtained  by  multiplying  the  Exercise  Price  in  effect
immediately  prior  to such  adjustment  by the  number  of  shares  purchasable
pursuant hereto  immediately prior to such adjustment,  and dividing the product
thereof by the Exercise Price resulting from such adjustment.
<PAGE>

     2.1  SUBDIVISION OR COMBINATION OF COMMON STOCK.  In case the Company shall
at any time subdivide or reclassify its outstanding  shares of Common Stock into
a greater number of shares,  the Exercise Price in effect  immediately  prior to
such subdivision shall be proportionately  reduced, and conversely,  in case the
outstanding  shares  of  Common  Stock  of the  Company  shall  be  combined  or
reclassified  into a smaller  number of  shares,  the  Exercise  Price in effect
immediately prior to such combination shall be proportionately increased.

     2.2 DIVIDENDS IN COMMON STOCK, OTHER STOCK, PROPERTY, RECLASSIFICATION.  If
at any time or from time to time the  holders of Common  Stock (or any shares of
stock or other securities at the time receivable upon the exercise of this Class
B Warrant) shall have received or become  entitled to receive,  without  payment
therefore:

          2.2.1  Stock,  Common  Stock or any shares of  capital  stock or other
     securities which are at any time directly or indirectly convertible into or
     exchangeable  for Common Stock,  or any rights or options to subscribe for,
     purchase or  otherwise  acquire any of the  foregoing by way of dividend or
     other distribution,

          2.2.2 Any cash paid or payable otherwise than as a cash dividend, or

          2.2.3  Stock,  Common  Stock  or  additional  capital  stock  or other
     securities  or  property  (including  cash)  by way of  spinoff,  split-up,
     reclassification, combination of shares or similar corporate rearrangement,
     (other than shares of Common Stock  issued as a stock split or  adjustments
     in respect of which  shall be covered by the terms of Section  2.1  above),
     then and in each such case,  the Holder hereof shall,  upon the exercise of
     this Class B Warrant,  be entitled to receive, in addition to the number of
     shares of Common Stock or other capital  stock  receivable  thereupon,  and
     without  payment of any additional  consideration  therefor,  the amount of
     stock  and  other  securities  and  property  (including  cash in the cases
     referred to in clause  (2.2.2)  above and this clause  (2.2.3))  which such
     Holder  would hold on the date of such  exercise  had he been the holder of
     record of such Common Stock as of the date on which holders of Common Stock
     received or became entitled to receive such shares or all other  additional
     stock and other securities and property.
<PAGE>

     2.3 REORGANIZATION, RECLASSIFICATION, CONSOLIDATION, MERGER OR SALE.

          2.3.1 If any  recapitalization,  reclassification or reorganization of
     the capital  stock of the Company,  or any  consolidation  or merger of the
     Company with another  corporation,  or the sale of all or substantially all
     of its assets or other  transaction  shall be  effected  in such a way that
     holders of Common Stock shall be entitled to receive stock, securities,  or
     other  assets or property (an "Organic  Change"),  then,  as a condition of
     such Organic Change,  lawful and adequate  provisions  shall be made by the
     Company  whereby the Holder hereof shall  thereafter  have the right,  upon
     exercise of this Class B Warrant,  to purchase  and receive (in lieu of the
     shares  of  the  Common  Stock  of  the  Company  immediately   theretofore
     purchasable and receivable  upon the exercise of the rights  represented by
     this Class B Warrant)  such shares of stock,  securities or other assets or
     property as may be issued or payable  with  respect to or in exchange for a
     number of  outstanding  shares of such Common  Stock equal to the number of
     shares of such stock  immediately  theretofore  purchasable  and receivable
     upon the exercise of the rights represented by this Class B Warrant. In the
     event of any Organic  Change,  appropriate  provision  shall be made by the
     Company  with  respect to the rights  and  interests  of the Holder of this
     Class B Warrant to the end that the provisions hereof  (including,  without
     limitation,  provisions  for  adjustments  of the Exercise Price and of the
     number of shares purchasable and receivable upon the exercise of this Class
     B Warrant)  shall  thereafter be  applicable,  in relation to any shares of
     stock,  securities  or  assets  thereafter  deliverable  upon the  exercise
     hereof. The Company will not effect any such consolidation,  merger or sale
     unless, prior to the consummation  thereof,  the successor  corporation (if
     other  than  the  Company)   resulting  from  such   consolidation  or  the
     corporation  purchasing  such  assets  shall  assume by written  instrument
     executed and mailed or  delivered to the Holder  hereof at the last address
     of such Holder  appearing on the books of the Company,  the  obligation  to
     deliver to such Holder,  upon Holder's exercise of this Class B Warrant and
     payment of the purchase  price in accordance  with the terms  hereof,  such
     shares of stock,  securities or assets as, in accordance with the foregoing
     provisions, such Holder may be entitled to purchase.

          2.3.2 No adjustment of the Exercise Price,  however,  shall be made in
     an amount less than $.01 per Share, but any such lesser adjustment shall be
     carried  forward and shall be made at the time and  together  with the next
     subsequent  adjustment  which  together  with any  adjustments  so  carried
     forward shall amount to $.01 per Share or more.
<PAGE>

     2.4 CERTAIN EVENTS.  If any change in the  outstanding  Common Stock of the
Company  or any other  event  occurs as to which  the other  provisions  of this
Section 2 are not strictly applicable or if strictly applicable would not fairly
protect the purchase  rights of the Holder of the Class B Warrant in  accordance
with such  provisions,  then the Board of Directors of the Company shall make an
adjustment  in the  number  and  class of  shares  available  under  the Class B
Warrant,  the Exercise  Price or the  application of such  provisions,  so as to
protect such purchase rights as aforesaid.  The adjustment shall be such as will
give the  Holder of the Class B Warrant  upon  exercise  for the same  aggregate
Exercise  Price the total number,  and kind of shares as he would have owned had
the Class B Warrant  been  exercised  prior to the event and had he continued to
hold such shares until after the event requiring adjustment.

     2.5 NOTICES OF CHANGE.

          2.5.1 Upon any  determination  or adjustment in the number or class of
     shares  subject  to this Class B Warrant  and of the  Exercise  Price,  the
     Company shall give written notice  thereof to the Holder,  setting forth in
     reasonable  detail and certifying the calculation of such  determination or
     adjustment.

          2.5.2 The Company shall give written  notice to the Holder at least 20
     business  days prior to the date on which the  Company  closes its books or
     takes  a  record  for  determining  rights  to  receive  any  dividends  or
     distributions.

          2.5.3 The  Company  shall  also give  written  notice to the Holder at
     least 20 days  prior to the date on which  an  Organic  Change  shall  take
     place.

3. ISSUE TAX. The issuance of  certificates  for shares of Common Stock upon the
exercise of the Class B Warrant  shall be made  without  charge to the Holder of
the Class B Warrant for any issue tax (other than any  applicable  income taxes)
in respect thereof; provided, however, that the Company shall not be required to
pay any tax which may be  payable in respect  of any  transfer  involved  in the
issuance and delivery of any  certificate  in a name other than that of the then
Holder of the Class B Warrant being exercised.

4.  CLOSING  OF BOOKS.  The  Company  will at no time close its  transfer  books
against the transfer of any warrant or of any shares of stock issued or issuable
upon the exercise of any warrant in any manner which  interferes with the timely
exercise of this Class B Warrant.
<PAGE>

5. NO VOTING OR DIVIDEND RIGHTS;  LIMITATION OF LIABILITY.  Nothing contained in
this Class B Warrant shall be construed as conferring upon the Holder hereof the
right to vote as a shareholder of the Company. No dividends or interest shall be
payable or accrued in respect of this Class B Warrant,  the interest represented
hereby, or the shares purchasable  hereunder until, and only to the extent that,
this Class B Warrant shall have been  exercised,  subject to the Holder's rights
under Section 2 of this Class B Warrant. No provisions hereof, in the absence of
affirmative action by the Holder to purchase shares of Common Stock, and no mere
enumeration herein of the rights or privileges of the Holder hereof,  shall give
rise to any liability of such Holder for the Exercise  Price or as a shareholder
of the  Company,  whether  such  liability  is asserted by the Company or by its
creditors.

6.  RIGHTS  AND  OBLIGATIONS  SURVIVE  EXERCISE  OF  WARRANT.   The  rights  and
obligations  of the  Company,  of the Holder of this Class B Warrant  and of the
holder of shares of Common Stock  issued upon  exercise of this Class B Warrant,
shall survive the exercise of this Class B Warrant.

7. FURTHER REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY.

     7.1  ARTICLES  AND BYLAWS.  The Company has made  available to Holder true,
complete  and  correct  copies of the Company  Charter  and Bylaws,  as amended,
through the date hereof.

     7.2 DUE AUTHORITY.  The execution and delivery by the Company of this Class
B Warrant and the  performance  of all  obligations  of the  Company  hereunder,
including  the  issuance  to Holder of the right to acquire the shares of Common
Stock,  have been duly authorized by all necessary  corporate action on the part
of the  Company,  and the Class B Warrant is not  inconsistent  with the Company
Charter or Bylaws and  constitutes a legal,  valid and binding  agreement of the
Company, enforceable in accordance with its terms.

     7.3 CONSENTS AND APPROVALS. No consent or approval of, giving of notice to,
registration  with,  or taking of any other  action  in  respect  of any  state,
federal or other  governmental  authority or agency is required  with respect to
the execution,  delivery and performance by the Company of its obligations under
this Class B Warrant,  except for any filing required by applicable  federal and
state  securities  laws,  which filing will be  effective  by the time  required
thereby.

     7.4 ISSUED  SECURITIES.  All issued and outstanding shares of capital stock
of the Company have been duly  authorized  and validly issued and are fully paid
and  nonassessable.  All outstanding shares of capital stock were issued in full
compliance with all federal and state securities laws.

     7.5  EXEMPT   TRANSACTION.   Subject  to  the   accuracy   of  the  Holders
representations  in Section 8 hereof,  the  issuance  of the  Common  Stock upon
exercise of this Class B Warrant will  constitute a transaction  exempt from (i)
the  registration  requirements  of Section 5 of the  Securities Act of 1933, as
amended  ("1933  Act"),  in reliance  upon  Section  4(2)  thereof,  or upon the
applicable exemption under Regulation D, and (ii) the qualification requirements
of the applicable state securities laws.
<PAGE>

     7.6  COMPLIANCE  WITH RULE 144. At the written  request of the Holder,  who
proposes to sell Common Stock  issuable upon the exercise of the Class B Warrant
in  compliance  with  Rule  144  promulgated  by  the  Securities  and  Exchange
Commission,  the Company shall furnish to the Holder, within five (5) days after
receipt of such request, a written statement confirming the Company's compliance
with the filing  requirements  of the Securities and Exchange  Commission as set
forth in such Rule, as such Rule may be amended from time to time.

     7.7  REGISTRATION.  The  shares of Common  Stock  underlying  this  Class B
Warrant  are subject to a  Registration  Rights  Agreement  dated as of the date
hereof between the Company and the Holder,  the terms of which are  incorporated
by reference herein.

8. REPRESENTATIONS AND COVENANTS OF THE HOLDER.

     8.1 This Class B Warrant has been  entered  into by the Company in reliance
upon the following representations and covenants of the Holder:

          8.1.1  Investment  Purpose.  The Class B Warrant or the  Common  Stock
     issuable  upon  exercise  of the  Class  B  Warrant  will be  acquired  for
     investment  and not  with a view to the  sale or  distribution  of any part
     thereof,  and the Holder has no present intention of selling or engaging in
     any public  distribution  of the same except  pursuant to a registration or
     exemption.

          8.1.2 Private Issue.

          a) The Holder  understands (i) that the Class B Warrant and the Common
     Stock  issuable  upon  exercise of this Class B Warrant are not  registered
     under the 1933 Act or qualified under  applicable  state securities laws on
     the ground that the issuance  contemplated  by this Class B Warrant will be
     exempt from the registration and qualifications  requirements  thereof, and
     (ii) that the  Company's  reliance on such  exemption is  predicated on the
     representations set forth in this Section 8.

          b) The Company will file a Registration  Statement covering the shares
     underlying the warrants at or before exercise date.
<PAGE>

          8.1.3  Disposition of Holders Rights. In no event will the Holder make
     a  disposition  of the Class B Warrant or the Common  Stock  issuable  upon
     exercise of the Class B Warrant unless and until (i) it shall have notified
     the  Company of the  proposed  disposition,  and (ii) if  requested  by the
     Company,  it shall have  furnished  the Company  with an opinion of counsel
     (which  counsel  may  either be inside or outside  counsel  to the  Holder)
     satisfactory  to the  Company  and  its  counsel  to the  effect  that  (A)
     appropriate  action  necessary  for  compliance  with the 1933 Act has been
     taken, or (B) an exemption from the  registration  requirements of the 1933
     Act is available.  Notwithstanding the foregoing,  the restrictions imposed
     upon the  transferability  of any of its  rights to  acquire  Common  Stock
     issuable on the exercise of such rights do not apply to transfers  from the
     beneficial owner of any of the aforementioned  securities to its nominee or
     from such nominee to its beneficial  owner,  and shall  terminate as to any
     particular   share  of  stock  when  (1)  such  security  shall  have  been
     effectively registered under the 1933 Act and sold by the Holder thereof in
     accordance with such registration or (2) such security shall have been sold
     without registration in compliance with Rule 144 under the 1933 Act, or (3)
     a letter  shall have been  issued to the Holder at its request by the staff
     of the  Securities  and  Exchange  Commission  or a ruling  shall have been
     issued to the Holder at its  request  by such  Commission  stating  that no
     action shall be recommended by such staff or taken by such  Commission,  as
     the case may be, if such security is transferred without registration under
     the 1933 Act in accordance  with the conditions set forth in such letter or
     ruling and such letter or ruling specifies that no subsequent  restrictions
     on transfer are required. Whenever the restrictions imposed hereunder shall
     terminate,  as  hereinabove  provided,  the  Holder or holder of a share of
     stock then outstanding as to which such  restrictions have terminated shall
     be entitled to receive  from the Company,  without  expense to such Holder,
     one or more new  certificates for the Class B Warrant or for such shares of
     stock not bearing any restrictive legend.

          8.1.4  Financial Risk. The Holder has such knowledge and experience in
     financial and business  matters as to be capable of  evaluating  the merits
     and risks of its investment, and has the ability to bear the economic risks
     of its investment.

          8.1.5  Risk of No  Registration.  The Holder  understands  that if the
     Company does not file  reports  pursuant to Section  15(d)  and/or  Section
     12(g),  of the  Securities  Exchange  Act of  1934  ("1934  Act"),  or if a
     registration statement covering the securities under the 1933 Act is not in
     effect when it desires to sell (i) the Class B Warrant,  or (ii) the Common
     Stock issuable upon exercise of the Class B Warrant,  it may be required to
     hold such securities for an indefinite  period. The Holder also understands
     that any sale of the Class B Warrant  or the  Common  Stock  issuable  upon
     exercise of the Class B Warrant  which might be made by it in reliance upon
     Rule 144 under the 1933 Act may be made only in  accordance  with the terms
     and conditions of that Rule.

          8.1.6  Accredited  Investor.  The Holder is an  "accredited  investor"
     within the meaning of Regulation D promulgated under the 1933 Act.
<PAGE>

9. MODIFICATION AND WAIVER. This Class B Warrant and any provision hereof may be
changed,  waived,  discharged  or  terminated  only by an  instrument in writing
signed by (a) the party against which  enforcement  of the same is sought or (b)
the  Company and the holders of at least a majority of the number of shares into
which the Class B Warrants are  exercisable  (without  regard to any  limitation
contained  herein  on  such  exercise),   it  being  understood  that  upon  the
satisfaction  of the  conditions  described  in (a) and (b) above,  each Class B
Warrant  (including  any Class B Warrant  held by the Holder who did not execute
the  agreement  specified  in (b)  above)  shall be  deemed to  incorporate  any
amendment,  modification,  change or waiver effected thereby as of the effective
date thereof.  Notwithstanding the foregoing,  no modification to this Section 9
will be effective against any Holder without his consent.

10.  TRANSFER OF THIS CLASS B WARRANT.  No  transfer  of this  Warrant can occur
without  written  consent  and  approval  by the  Company.  If such  approval is
granted, then the Holder may sell, transfer, assign, pledge or otherwise dispose
of this  Class B  Warrant,  in whole or in part,  as long as such  sale or other
disposition  is made  pursuant  to an  effective  registration  statement  or an
exemption from the  registration  requirements  of the Securities Act. Upon such
transfer or other  disposition  (other than a pledge),  the Holder shall deliver
this  Warrant to the  Company  together  with a written  notice to the  Company,
substantially  in the form of the Transfer  Notice  attached hereto as Exhibit B
(the "Transfer  Notice"),  indicating the person or persons to whom this Class B
Warrant  shall be  transferred  and, if less than all of this Class B Warrant is
transferred,  the  number of  Warrant  Shares to be  covered by the part of this
Class B Warrant to be transferred to each such person. Within three (3) Business
Days of  receiving a Transfer  Notice and the  original of this Class B Warrant,
the Company  shall  deliver to the each  transferee  designated  by the Holder a
Class B Warrant(s) of like tenor and terms for the appropriate number of Warrant
Shares and, if less than all this Class B Warrant is transferred,  shall deliver
to the Holder a Class B Warrant for the remaining number of Warrant Shares.

11.  NOTICES.  Any notice  required  or  permitted  hereunder  shall be given in
writing  (unless  otherwise  specified  herein) and shall be deemed  effectively
given upon (i) personal delivery, against written receipt thereof, (ii) delivery
via facsimile or e-mail as set forth below (iii) two business days after deposit
with Federal Express or another nationally recognized overnight courier service,
or (iv) five business days after being forwarded, postage paid, via certified or
registered  mail,  return  receipt  requested,  addressed  to each of the  other
parties  thereunto  entitled  at  the  following  addresses,  or at  such  other
addresses as a party may designate by ten days advance written notice.
<PAGE>

12.  BINDING EFFECT ON  SUCCESSORS;  BENEFIT.  As provided in Section 2.3 above,
this  Class B Warrant  shall be  binding  upon any  corporation  succeeding  the
Company by merger,  consolidation or acquisition of all or substantially  all of
the Company's  assets.  All of the  obligations  of the Company  relating to the
Common Stock  issuable  upon the exercise of this Class B Warrant  shall survive
the exercise and  termination of this Class B Warrant.  All of the covenants and
agreements  of the  Company  shall inure to the  benefit of the  successors  and
assigns of the Holder  hereof.  This Series A Warrant  shall be for the sole and
exclusive  benefit of the Holder and nothing in this  Series A Warrant  shall be
construed to confer upon any person other than the Holder any legal or equitable
right, remedy or claim hereunder.

13.  DESCRIPTIVE  HEADINGS AND GOVERNING  LAW. The  description  headings of the
several  sections  and  paragraphs  of this  Class B Warrant  are  inserted  for
convenience  only and do not  constitute  a part of this Class B  Warrant.  This
Class B Warrant  shall be construed  and enforced in  accordance  with,  and the
rights of the parties shall be governed by the laws of the State of Utah.

14. LOST WARRANTS. The Company represents and warrants to the Holder hereof that
upon  receipt of evidence  reasonably  satisfactory  to the Company of the loss,
theft,  destruction,  or  mutilation of this Class B Warrant and, in the case of
any such loss,  theft or  destruction,  upon receipt of an indemnity  reasonably
satisfactory  to  the  Company,  or in the  case  of any  such  mutilation  upon
surrender and cancellation of such Class B Warrant, the Company, at the Holder's
expense,  will make and deliver a new Class B Warrant, of like tenor, in lieu of
the lost, stolen, destroyed or mutilated Class B Warrant.

15.  FRACTIONAL  SHARES.  No fractional  shares shall be issued upon exercise of
this Class B Warrant.  The  Company  shall,  in lieu of issuing  any  fractional
share,  pay the  Holder  entitled  to such  fraction a sum in cash equal to such
fraction multiplied by the then effective Exercise Price.

16.  REDEMPTION.  This Class B Warrant may be called for redemption and redeemed
at the option of the Company, at a redemption price of $.50 per Class B Warrant,
at any time between the  Effective  Date of the  Registration  Statement and the
Expiration  Date upon 10 day written notice  delivered to the Holder,  provided:
(a) the  Closing  Bid or last sales  price of the  Common  Stock  issuable  upon
exercise  of such Class B Warrant has been at least 175% of the  Exercise  Price
for twenty (20)  consecutive  trading  days ending not more than 3 days prior to
the  date of  notice  of  redemption;  (b)  there is an  effective  registration
statement  with a current  prospectus  available  covering  the shares of Common
Stock  issuable  upon  exercise  of this  Class  B  Warrant;  and (c) no  public
announcement  of a pending or proposed  Organic Change has occurred that has not
been consummated. If any of the foregoing conditions shall cease to be satisfied
at any time during the required period, then the Holder may elect to nullify the
Redemption Notice in which case the Redemption Notice shall be null and void, ab
initio.  On and after the date fixed for  redemption,  the Holder  shall have no
rights with respect to this Class B Warrant except to receive the $.50 per Class
B Warrant  upon  surrender  of this  Certificate.  All Class B Warrants  must be
redeemed  if any are  redeemed.  The Company  covenants  and agrees that it will
honor all  Exercise  Notices  tendered  through  the  Business  Day  immediately
preceding the Redemption  Date. The redemption  payment shall be made in cash on
date fixed for redemption in the Company's  notice of  redemption,  as described
below (the  "Redemption  Date").  The  redemption  payment is due in full on the
Redemption Date.
<PAGE>

         The notice of redemption shall specify:  (i) the Redemption Price; (ii)
the date fixed for redemption  (the  "Redemption  Date");  (iii) the place where
Class B Warrant  Certificates  shall be delivered and the redemption price paid;
and (iv) that the right to exercise the Class B Warrants shall terminate at 5:00
p.m. EST on the Business Day  immediately  preceding  the  Redemption  Date.  An
affidavit of the Secretary or an Assistant  Secretary of the Company that notice
of  redemption  has been mailed  shall,  in the absence of fraud,  be conclusive
evidence of the facts stated therein.

         From and after the Redemption  Date,  the Company  shall,  at the place
specified in the notice of redemption,  upon  presentation  and surrender to the
Company by or on behalf of the Holder  thereof of this Class B Warrant,  deliver
or cause to be  delivered  to or upon the written  order of such holder a sum of
cash equal to the Redemption Price of each such Class B Warrant.  From and after
the  Redemption  Date and upon the deposit or setting  aside by the Company of a
sum sufficient to redeem all the Class B Warrants  called for  redemption,  such
Class B Warrants shall expire and become void and all rights hereunder and shall
cease, except the right, if any, to receive payment of the Redemption Price.

         IN WITNESS  WHEREOF,  the Company  has caused  this  Warrant to be duly
executed by its officers,  thereunto duly  authorized this [ ] day of _________,
200__.

                                        -------------------------------

<PAGE>

                                   SCHEDULE A

                                SUBSCRIPTION FORM

Date:  _________________, _______

Implantable Vision, Inc. - Attn:  President

Ladies and Gentlemen:

         The undersigned hereby elects to exercise the Class B Warrant issued to
it  by  Implantable  Vision,  Inc.   ("Company")  and  dated  ______  ___  ____,
("Warrant") and to purchase thereunder __________________________________ shares
of the  Common  Stock of the  Company  ("Shares")  at a  purchase  price of five
dollars ($5.00) per Share or an aggregate  purchase price of  __________________
________________ Dollars ($__________) ("Exercise Price").

         Pursuant to the terms of the Warrant, the undersigned has delivered the
Exercise Price herewith in full in cash or by certified check or wire transfer.

                                                     Very truly yours,

<PAGE>

                                   ASSIGNMENT

                          To Be Executed by the Holder
                           in Order to Assign Warrants

FOR VALUE RECEIVED,  ________________________________  hereby sells, assigns and
transfers unto

            PLEASE INSERT SOCIAL SECURITY OR OTHER IDENTIFYING NUMBER

                                  --------------------------------------

                                  --------------------------------------

                                  --------------------------------------
                                  [please print or type name and address]

_____________________of the Class B Warrants represented by this Class B Warrant
Certificate,     and    hereby    irrevocably     constitutes    and    appoints
_________________________________________  Attorney  to  transfer  this  Class B
Warrant Certificate on the books of the Company, with full power of substitution
in the premises.

Dated:                            x
       -----------------          -------------------------------------------
                                     Signature Guaranteed

THE SIGNATURE TO THE ASSIGNMENT OR THE SUBSCRIPTION  FORM MUST CORRESPOND TO THE
NAME AS  WRITTEN  UPON THE FACE OF THIS  CLASS A  WARRANT  CERTIFICATE  IN EVERY
PARTICULAR, WITHOUT ALTERATION OR ENLARGEMENT OR ANY CHANGE WHATSOEVER, AND MUST
BE  GUARANTEED  BY A  COMMERCIAL  BANK OR TRUST  COMPANY OR A MEMBER FIRM OF THE
AMERICAN  STOCK  EXCHANGE,  NEW YORK STOCK  EXCHANGE,  PACIFIC STOCK EXCHANGE OR
MIDWEST STOCK EXCHANGE.SECURITIES PURCHASE AGREEMENT

SECURITIES PURCHASE AGREEMENT

SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of November 29, 2005, by and among INFE, Human Resources, Inc., a Nevada corporation, with headquarters located at 67 Wall Street, 22nd Floor, New York, NY 10005 (the “Company”), and each of the purchasers set forth on the signature pages hereto (the “Buyers”).

WHEREAS: 

A.

The Company and the Buyers are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by the rules and regulations as promulgated by the United States Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended (the “1933 Act”);

B.

Buyers desire to purchase and the Company desires to issue and sell, upon the terms and conditions set forth in this Agreement (i) 8% secured convertible notes of the Company, in the form attached hereto as Exhibit “A”, in the aggregate principal amount of Three Million Dollars ($3,000,000) (together with any note(s) issued in replacement thereof or as a dividend thereon or otherwise with respect thereto in accordance with the terms thereof, the “Notes”), convertible into shares of  common stock, par value $.001 per share, of the Company (the “Common Stock”), upon the terms and subject to the limitations and conditions set forth in such Notes and (ii) warrants, in the form attached hereto as Exhibit “B”, to purchase 1,200,000 shares of Common Stock (the “Warrants”).

C.

Each Buyer wishes to purchase, upon the terms and conditions stated in this Agreement, such principal amount of Notes and number of Warrants as is set forth immediately below its name on the signature pages hereto; and

D.

Contemporaneous with the execution and delivery of this Agreement, the parties hereto are executing and delivering a Registration Rights Agreement, in the form attached hereto as Exhibit “C” (the “Registration Rights Agreement”), pursuant to which the Company has agreed to provide certain registration rights under the 1933 Act and the rules and regulations promulgated thereunder, and applicable state securities laws.

NOW THEREFORE, the Company and each of the Buyers severally (and not jointly) hereby agree as follows:

1.

PURCHASE AND SALE OF NOTES AND WARRANTS.

a.

Purchase of Notes and Warrants.  On the Closing Date (as defined below), the Company shall issue and sell to each Buyer and each Buyer severally agrees to purchase from the Company such principal amount of Notes and number of Warrants as is set forth immediately below such Buyer’s name on the signature pages hereto.

b.

Form of Payment.  On the Closing Date (as defined below), (i) each Buyer shall pay the purchase price for the Notes and the Warrants to be issued and sold to it at the Closing (as defined below) (the “Purchase Price”) by wire transfer of immediately available funds to the Company, in accordance with the Company’s written wiring instructions, against delivery of the Notes in the principal amount equal to the Purchase Price and the number of Warrants as is set forth immediately below such Buyer’s name on the signature pages hereto, and (ii) the Company shall deliver such Notes and Warrants duly executed on behalf of the Company, to such Buyer, against delivery of such Purchase Price. 

c.

Closing Date.  Subject to the satisfaction (or written waiver) of the conditions thereto set forth in Section 6 and Section 7 below, the date and time of the issuance and sale of the Notes and the Warrants pursuant to this Agreement (the “Closing Date”) shall be 12:00 noon, Eastern Standard Time on November 29, 2005, or such other mutually agreed upon time.  The closing of the transactions contemplated by this Agreement (the “Closing”) shall occur on the Closing Date at such location as may be agreed to by the parties.

2.

BUYERS’ REPRESENTATIONS AND WARRANTIES.  Each Buyer severally (and not jointly) represents and warrants to the Company solely as to such Buyer that:

a.

Investment Purpose.  As of the date hereof, the Buyer is purchasing the Notes and the shares of Common Stock issuable upon conversion of or otherwise pursuant to the Notes (including, without limitation, such additional shares of Common Stock, if any, as are issuable (i) on account of interest on the Notes, (ii) as a result of the events described in Sections 1.3 and 1.4(g) of the Notes and Section 2(c) of the Registration Rights Agreement or (iii) in payment of the Standard Liquidated Damages Amount (as defined in Section 2(f) below) pursuant to this Agreement, such shares of Common Stock being collectively referred to herein as the “Conversion Shares”) and the Warrants and the shares of Common Stock issuable upon exercise thereof (the “Warrant Shares” and, collectively with the Notes, Warrants and Conversion Shares, the “Securities”) for its own account and not with a present view towards the public sale or distribution thereof, except pursuant to sales registered or exempted from registration under the 1933 Act; provided, however, that by making the representations herein, the Buyer does not agree to hold any of the Securities for any minimum or other specific term and reserves the right to dispose of the Securities at any time in accordance with or pursuant to a registration statement or an exemption under the 1933 Act.

b.

Accredited Investor Status.  The Buyer is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D (an “Accredited Investor”).

c.

Reliance on Exemptions.  The Buyer understands that the Securities are being offered and sold to it in reliance upon specific exemptions from the registration requirements of United States federal and state securities laws and that the Company is relying upon the truth and accuracy of, and the Buyer’s compliance with, the representations, warranties, agreements, acknowledgments and understandings of the Buyer set forth herein in order to determine the availability of such exemptions and the eligibility of the Buyer to acquire the Securities.

2

d.

Information.  The Buyer and its advisors, if any, have been, and for so long as the Notes and Warrants remain outstanding will continue to be, furnished with all materials relating to the business, finances and operations of the Company and materials relating to the offer and sale of the Securities which have been requested by the Buyer or its advisors.  The Buyer and its advisors, if any, have been, and for so long as the Notes and Warrants remain outstanding will continue to be, afforded the opportunity to ask questions of the Company.  Notwithstanding the foregoing, the Company has not disclosed to the Buyer any material nonpublic information and will not disclose such information unless such information is disclosed to the public prior to or promptly following such disclosure to the Buyer.  Neither such inquiries nor any other due diligence investigation conducted by Buyer or any of its advisors or representatives shall modify, amend or affect Buyer’s right to rely on the Company’s representations and warranties contained in Section 3 below.  The Buyer understands that its investment in the Securities involves a significant degree of risk.

e.

Governmental Review.  The Buyer understands that no United States federal or state agency or any other government or governmental agency has passed upon or made any recommendation or endorsement of the Securities.

f.

Transfer or Re-sale.  The Buyer understands that (i) except as provided in the Registration Rights Agreement, the sale or re-sale of the Securities has not been and is not being registered under the 1933 Act or any applicable state securities laws, and the Securities may not be transferred unless (a) the Securities are sold pursuant to an effective registration statement under the 1933 Act, (b) the Buyer shall have delivered to the Company an opinion of counsel that shall be in form, substance and scope customary for opinions of counsel in comparable transactions to the effect that the Securities to be sold or transferred may be sold or transferred pursuant to an exemption from such registration, which opinion shall be accepted by the Company, (c) the Securities are sold or transferred to an “affiliate” (as defined in Rule 144 promulgated under the 1933 Act (or a successor rule) (“Rule 144”)) of the Buyer who agrees to sell or otherwise transfer the Securities only in accordance with this Section 2(f) and who is an Accredited Investor, (d) the Securities are sold pursuant to Rule 144, or (e) the Securities are sold pursuant to Regulation S under the 1933 Act (or a successor rule) (“Regulation S”), and the Buyer shall have delivered to the Company an opinion of counsel that shall be in form, substance and scope customary for opinions of counsel in corporate transactions, which opinion shall be accepted by the Company; (ii) any sale of such Securities made in reliance on Rule 144 may be made only in accordance with the terms of said Rule and further, if said Rule is not applicable, any re-sale of such Securities under circumstances in which the seller (or the person through whom the sale is made) may be deemed to be an underwriter (as that term is defined in the 1933 Act) may require compliance with some other exemption under the 1933 Act or the rules and regulations of the SEC thereunder; and (iii) neither the Company nor any other person is under any obligation to register such Securities under the 1933 Act or any state securities laws or to comply with the terms and conditions of any exemption thereunder (in each case, other than pursuant to the Registration Rights Agreement).  Notwithstanding the foregoing or anything else contained herein to the contrary, the Securities may be pledged as collateral in connection with a bona fide margin account or other lending arrangement.  In the event that the Company does not accept the opinion of counsel provided by the Buyer with respect to the transfer of Securities pursuant to an exemption from registration, such as Rule 144 or Regulation S, within three (3) business days of delivery of the opinion to the Company, the Company shall pay to the Buyer liquidated damages of three percent (3%) of the outstanding amount of the Notes per month plus accrued and unpaid interest on the Notes, prorated for partial months, in cash or shares at the option of the Company (“Standard Liquidated Damages Amount”).  If the Company elects to be pay the Standard Liquidated Damages Amount in shares of Common Stock, such shares shall be issued at the Conversion Price at the time of payment.

3

 

g.

Legends.  The Buyer understands that the Notes and the Warrants and, until such time as the Conversion Shares and Warrant Shares have been registered under the 1933 Act as contemplated by the Registration Rights Agreement or otherwise may be sold pursuant to Rule 144 or Regulation S without any restriction as to the number of securities as of a particular date that can then be immediately sold, the Conversion Shares and Warrant Shares may bear a restrictive legend in substantially the following form (and a stop-transfer order may be placed against transfer of the certificates for such Securities):

“The securities represented by this certificate have not been registered under the Securities Act of 1933, as amended.  The securities may not be sold, transferred or assigned in the absence of an effective registration statement for the securities under said Act, or an opinion of counsel, in form, substance and scope customary for opinions of counsel in comparable transactions, that registration is not required under said Act or unless sold pursuant to Rule 144 or Regulation S under said Act.”

The legend set forth above shall be removed and the Company shall issue a certificate without such legend to the holder of any Security upon which it is stamped, if, unless otherwise required by applicable state securities laws, (a) such Security is registered for sale under an effective registration statement filed under the 1933 Act or otherwise may be sold pursuant to Rule 144 or Regulation S without any restriction as to the number of securities as of a particular date that can then be immediately sold, or (b) such holder provides the Company with an opinion of counsel, in form, substance and scope customary for opinions of counsel in comparable transactions, to the effect that a public sale or transfer of such Security may be made without registration under the 1933 Act, which opinion shall be accepted by the Company so that the sale or transfer is effected or (c) such holder provides the Company with reasonable assurances that such Security can be sold pursuant to Rule 144 or Regulation S.  The Buyer agrees to sell all Securities, including those represented by a certificate(s) from which the legend has been removed, in compliance with applicable prospectus delivery requirements, if any.

h.

Authorization; Enforcement. This Agreement and the Registration Rights Agreement have been duly and validly authorized.  This Agreement has been duly executed and delivered on behalf of the Buyer, and this Agreement constitutes, and upon execution and delivery by the Buyer of the Registration Rights Agreement, such agreement will constitute, valid and binding agreements of the Buyer enforceable in accordance with their terms.

i.

Residency.  The Buyer is a resident of the jurisdiction set forth immediately below such Buyer’s name on the signature pages hereto. 

 

4

 

3.

REPRESENTATIONS AND WARRANTIES OF THE COMPANY.  The Company represents and warrants to each Buyer that:

a.

Organization and Qualification.  The Company and each of its Subsidiaries (as defined below), if any, is a corporation duly organized, validly existing and in good standing under the laws of the jurisdiction in which it is incorporated, with full power and authority (corporate and other) to own, lease, use and operate its properties and to carry on its business as and where now owned, leased, used, operated and conducted.  Schedule 3(a) sets forth a list of all of the Subsidiaries of the Company and the jurisdiction in which each is incorporated.  The Company and each of its Subsidiaries is duly qualified as a foreign corporation to do business and is in good standing in every jurisdiction in which its ownership or use of property or the nature of the business conducted by it makes such qualification necessary except where the failure to be so qualified or in good standing would not have a Material Adverse Effect.  “Material Adverse Effect” means any of (i) a material and adverse effect on the legality, validity or enforceability of any document executed in connection with this financing, (ii) a material and adverse effect on the results of operations, assets, prospects, business or condition (financial or otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii) an adverse impairment to the Company’s ability to perform under any of the documents executed in connection with this financing.  “Subsidiaries” means any corporation or other organization, whether incorporated or unincorporated, in which the Company owns, directly or indirectly, any equity or other ownership interest.

b.

Authorization; Enforcement.  (i) The Company has all requisite corporate power and authority to enter into and perform this Agreement, the Registration Rights Agreement, the Notes and the Warrants and to consummate the transactions contemplated hereby and thereby and to issue the Securities, in accordance with the terms hereof and thereof, (ii) the execution and delivery of this Agreement, the Registration Rights Agreement, the Notes and the Warrants by the Company and the consummation by it of the transactions contemplated hereby and thereby (including without limitation, the issuance of the Notes and the Warrants and the issuance and reservation for issuance of the Conversion Shares and Warrant Shares issuable upon conversion or exercise thereof) have been duly authorized by the Company’s Board of Directors and no further consent or authorization of the Company, its Board of Directors, or its shareholders is required, (iii) this Agreement has been duly executed and delivered by the Company by its authorized representative, and such authorized representative is the true and official representative with authority to sign this Agreement and the other documents executed in connection herewith and bind the Company accordingly, and (iv) this Agreement constitutes, and upon execution and delivery by the Company of the Registration Rights Agreement, the Notes and the Warrants, each of such instruments will constitute, a legal, valid and binding obligation of the Company enforceable against the Company in accordance with its terms.

5

c.

Capitalization.  As of the date hereof, the authorized capital stock of the Company consists of (i) 100,000,000 shares of Common Stock, of which [        ] shares are issued and outstanding, [                 ] shares are reserved for issuance pursuant to the Company’s stock option plans, [             ] shares are reserved for issuance pursuant to securities (other than the Notes and the Warrants) exercisable for, or convertible into or exchangeable for shares of Common Stock and, 12,238,462 shares are reserved for issuance upon conversion of the Notes and exercise of the Warrants (subject to adjustment pursuant to the Company’s covenant set forth in Section 4(h) below); and (ii) [     ]  shares of preferred stock of which [        ] shares are issued and outstanding.  All of such outstanding shares of capital stock are, or upon issuance will be, duly authorized, validly issued, fully paid and nonassessable.  No shares of capital stock of the Company are subject to preemptive rights or any other similar rights of the shareholders of the Company or any liens or encumbrances imposed through the actions or failure to act of the Company.  Except as disclosed in Schedule 3(c), as of the effective date of this Agreement, (i) there are no outstanding options, warrants, scrip, rights to subscribe for, puts, calls, rights of first refusal, agreements, understandings, claims or other commitments or rights of any character whatsoever relating to, or securities or rights convertible into or exchangeable for any shares of capital stock of the Company or any of its Subsidiaries, or arrangements by which the Company or any of its Subsidiaries is or may become bound to issue additional shares of capital stock of the Company or any of its Subsidiaries, (ii) there are no agreements or arrangements under which the Company or any of its Subsidiaries is obligated to register the sale of any of its or their securities under the 1933 Act (except the Registration Rights Agreement) and (iii) there are no anti-dilution or price adjustment provisions contained in any security issued by the Company (or in any agreement providing rights to security holders) that will be triggered by the issuance of the Notes, the Warrants, the Conversion Shares or Warrant Shares.  The Company has furnished to the Buyer true and correct copies of the Company’s Certificate of Incorporation as in effect on the date hereof (“Certificate of Incorporation”), the Company’s By-laws, as in effect on the date hereof (the “By-laws”), and the terms of all securities convertible into or exercisable for Common Stock of the Company and the material rights of the holders thereof in respect thereto.  The Company shall provide the Buyer with a written update of this representation signed by the Company’s Chief Executive or Chief Financial Officer on behalf of the Company as of the Closing Date.

d.

Issuance of Shares.  The Conversion Shares and Warrant Shares are duly authorized and reserved for issuance and, upon conversion of the Notes and exercise of the Warrants in accordance with their respective terms, will be validly issued, fully paid and non-assessable, and free from all taxes, liens, claims and encumbrances with respect to the issue thereof and shall not be subject to preemptive rights or other similar rights of shareholders of the Company and will not impose personal liability upon the holder thereof.

e.

Acknowledgment of Dilution.  The Company understands and acknowledges the potentially dilutive effect to the Common Stock upon the issuance of the Conversion Shares and Warrant Shares upon conversion of the Note or exercise of the Warrants.  The Company further acknowledges that its obligation to issue Conversion Shares and Warrant Shares upon conversion of the Notes or exercise of the Warrants in accordance with this Agreement, the Notes and the Warrants is absolute and unconditional regardless of the dilutive effect that such issuance may have on the ownership interests of other shareholders of the Company.

6

f.

No Conflicts.  The execution, delivery and performance of this Agreement, the Registration Rights Agreement, the Notes and the Warrants by the Company and the consummation by the Company of the transactions contemplated hereby and thereby (including, without limitation, the issuance and reservation for issuance of the Conversion Shares and Warrant Shares) will not (i) conflict with or result in a violation of any provision of the Certificate of Incorporation or By-laws or (ii) violate or conflict with, or result in a breach of any provision of, or constitute a default (or an event which with notice or lapse of time or both could become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture, patent, patent license or instrument to which the Company or any of its Subsidiaries is a party, or (iii)  result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws and regulations and regulations of any self-regulatory organizations to which the Company or its securities are subject) applicable to the Company or any of its Subsidiaries or by which any property or asset of the Company or any of its Subsidiaries is bound or affected (except for such conflicts, defaults, terminations, amendments, accelerations, cancellations and violations as would not, individually or in the aggregate, have a Material Adverse Effect).  Neither the Company nor any of its Subsidiaries is in violation of its Certificate of Incorporation, By-laws or other organizational documents and neither the Company nor any of its Subsidiaries is in default (and no event has occurred which with notice or lapse of time or both could put the Company or any of its Subsidiaries in default) under, and neither the Company nor any of its Subsidiaries has taken any action or failed to take any action that would give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Company or any of its Subsidiaries is a party or by which any property or assets of the Company or any of its Subsidiaries is bound or affected, except for possible defaults as would not, individually or in the aggregate, have a Material Adverse Effect. The businesses of the Company and its Subsidiaries, if any, are not being conducted, and shall not be conducted so long as a Buyer owns any of the Securities, in violation of any law, ordinance or regulation of any governmental entity.  Except as specifically contemplated by this Agreement and as required under the 1933 Act and any applicable state securities laws, the Company is not required to obtain any consent, authorization or order of, or make any filing or registration with, any court, governmental agency, regulatory agency, self regulatory organization or stock market or any third party in order for it to execute, deliver or perform any of its obligations under this Agreement, the Registration Rights Agreement, the Notes or the Warrants in accordance with the terms hereof or thereof or to issue and sell the Notes and Warrants in accordance with the terms hereof and to issue the Conversion Shares upon conversion of the Notes and the Warrant Shares upon exercise of the Warrants.  Except as disclosed in Schedule 3(f), all consents, authorizations, orders, filings and registrations which the Company is required to obtain pursuant to the preceding sentence have been obtained or effected on or prior to the date hereof.  The Company is not in violation of the quotation requirements of the Over-the-Counter Bulletin Board (the “OTCBB”) and does not reasonably anticipate that the Common Stock will be delisted by the OTCBB in the foreseeable future.  The Company and its Subsidiaries are unaware of any facts or circumstances which might give rise to any of the foregoing.  

7

g.

SEC Documents; Financial Statements.  Except as disclosed in Schedule 3(g), the Company has timely filed all reports, schedules, forms, statements and other documents required to be filed by it with the SEC pursuant to the reporting requirements of the Securities Exchange Act of 1934, as amended (the “1934 Act”) (all of the foregoing filed prior to the date hereof and all exhibits included therein and financial statements and schedules thereto and documents (other than exhibits to such documents) incorporated by reference therein, being hereinafter referred to herein as the “SEC Documents”).  The Company has delivered to each Buyer true and complete copies of the SEC Documents, except for such exhibits and incorporated documents.  As of their respective dates, the SEC Documents complied in all material respects with the requirements of the 1934 Act and the rules and regulations of the SEC promulgated thereunder applicable to the SEC Documents, and none of the SEC Documents, at the time they were filed with the SEC, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading.  None of the statements made in any such SEC Documents is, or has been, required to be amended or updated under applicable law (except for such statements as have been amended or updated in subsequent filings prior the date hereof).  As of their respective dates, the financial statements of the Company included in the SEC Documents complied as to form in all material respects with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto.  Such financial statements have been prepared in accordance with United States generally accepted accounting principles, consistently applied, during the periods involved (except (i) as may be otherwise indicated in such financial statements or the notes thereto, or (ii) in the case of unaudited interim statements, to the extent they may not include footnotes or may be condensed or summary statements) and fairly present in all material respects the consolidated financial position of the Company and its consolidated Subsidiaries as of the dates thereof and the consolidated results of their operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments).  Except as set forth in the financial statements of the Company included in the SEC Documents, the Company has no liabilities, contingent or otherwise, other than (i) liabilities incurred in the ordinary course of business subsequent to June 30, 2004 and (ii) obligations under contracts and commitments incurred in the ordinary course of business and not required under generally accepted accounting principles to be reflected in such financial statements, which, individually or in the aggregate, are not material to the financial condition or operating results of the Company.

h.

Absence of Certain Changes.  Since June 30, 2004, there has been no material adverse change and no material adverse development in the assets, liabilities, business, properties, operations, financial condition, results of operations or prospects of the Company or any of its Subsidiaries.

8

i.

Absence of Litigation.  There is no action, suit, claim, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the Company or any of its Subsidiaries, threatened against or affecting the Company or any of its Subsidiaries, or their officers or directors in their capacity as such, that could have a Material Adverse Effect.  Schedule 3(i) contains a complete list and summary description of any pending or threatened proceeding against or affecting the Company or any of its Subsidiaries, without regard to whether it would have a Material Adverse Effect.  The Company and its Subsidiaries are unaware of any facts or circumstances which might give rise to any of the foregoing.

j.

Patents, Copyrights, etc.  The Company and each of its Subsidiaries owns or possesses the requisite licenses or rights to use all patents, patent applications, patent rights, inventions, know-how, trade secrets, trademarks, trademark applications, service marks, service names, trade names and copyrights (“Intellectual Property”) necessary to enable it to conduct its business as now operated (and, except as set forth in Schedule 3(j) hereof, to the best of the Company’s knowledge, as presently contemplated to be operated in the future); there is no claim or action by any person pertaining to, or proceeding pending, or to the Company’s knowledge threatened, which challenges the right of the Company or of a Subsidiary with respect to any Intellectual Property necessary to enable it to conduct its business as now operated (and, except as set forth in Schedule 3(j) hereof, to the best of the Company’s knowledge, as presently contemplated to be operated in the future); to the best of the Company’s knowledge, the Company’s or its Subsidiaries’ current and intended products, services and processes do not infringe on any Intellectual Property or other rights held by any person; and the Company is unaware of any facts or circumstances which might give rise to any of the foregoing.  The Company and each of its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of their Intellectual Property.

k.

No Materially Adverse Contracts, Etc.  Neither the Company nor any of its Subsidiaries is subject to any charter, corporate or other legal restriction, or any judgment, decree, order, rule or regulation which in the judgment of the Company’s officers has or is expected in the future to have a Material Adverse Effect.  Neither the Company nor any of its Subsidiaries is a party to any contract or agreement which in the judgment of the Company’s officers has or is expected to have a Material Adverse Effect.

9

l.

Tax Status.  Except as set forth on Schedule 3(l), the Company and each of its Subsidiaries has made or filed all federal, state and foreign income and all other tax returns, reports and declarations required by any jurisdiction to which it is subject (unless and only to the extent that the Company and each of its Subsidiaries has set aside on its books provisions reasonably adequate for the payment of all unpaid and unreported taxes) and has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations, except those being contested in good faith and has set aside on its books provisions reasonably adequate for the payment of all taxes for periods subsequent to the periods to which such returns, reports or declarations apply.  There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company know of no basis for any such claim.  The Company has not executed a waiver with respect to the statute of limitations relating to the assessment or collection of any foreign, federal, state or local tax.  Except as set forth on Schedule 3(l), none of the Company’s tax returns is presently being audited by any taxing authority.

m.

Certain Transactions.  Except as set forth on Schedule 3(m) and except for arm’s length transactions pursuant to which the Company or any of its Subsidiaries makes payments in the ordinary course of business upon terms no less favorable than the Company or any of its Subsidiaries could obtain from third parties and other than the grant of stock options disclosed on Schedule 3(c), none of the officers, directors, or employees of the Company is presently a party to any transaction with the Company or any of its Subsidiaries (other than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any corporation, partnership, trust or other entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee or partner.

n.

Disclosure.  All information relating to or concerning the Company or any of its Subsidiaries set forth in this Agreement and provided to the Buyers pursuant to Section 2(d) hereof and otherwise in connection with the transactions contemplated hereby is true and correct in all material respects and the Company has not omitted to state any material fact necessary in order to make the statements made herein or therein, in light of the circumstances under which they were made, not misleading.  No event or circumstance has occurred or exists with respect to the Company or any of its Subsidiaries or its or their business, properties, prospects, operations or financial conditions, which, under applicable law, rule or regulation, requires public disclosure or announcement by the Company but which has not been so publicly announced or disclosed (assuming for this purpose that the Company’s reports filed under the 1934 Act are being incorporated into an effective registration statement filed by the Company under the 1933 Act).

10

o.

Acknowledgment Regarding Buyers’ Purchase of Securities.  The Company acknowledges and agrees that the Buyers are acting solely in the capacity of arm’s length purchasers with respect to this Agreement and the transactions contemplated hereby.  The Company further acknowledges that no Buyer is acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to this Agreement and the transactions contemplated hereby and any statement made by any Buyer or any of their respective representatives or agents in connection with this Agreement and the transactions contemplated hereby is not advice or a recommendation and is merely incidental to the Buyers’ purchase of the Securities.  The Company further represents to each Buyer that the Company’s decision to enter into this Agreement has been based solely on the independent evaluation of the Company and its representatives.

p.

No Integrated Offering.  Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf, has directly or indirectly made any offers or sales in any security or solicited any offers to buy any security under circumstances that would require registration under the 1933 Act of the issuance of the Securities to the Buyers.  The issuance of the Securities to the Buyers will not be integrated with any other issuance of the Company’s securities (past, current or future) for purposes of any shareholder approval provisions applicable to the Company or its securities.

q.

No Brokers.  Except as set forth in Schedule 3(q), the Company has taken no action which would give rise to any claim by any person for brokerage commissions, transaction fees or similar payments relating to this Agreement or the transactions contemplated hereby. 

r.

Permits; Compliance.  The Company and each of its Subsidiaries is in possession of all franchises, grants, authorizations, licenses, permits, easements, variances, exemptions, consents, certificates, approvals and orders necessary to own, lease and operate its properties and to carry on its business as it is now being conducted (collectively, the “Company Permits”), and there is no action pending or, to the knowledge of the Company, threatened regarding suspension or cancellation of any of the Company Permits.  Neither the Company nor any of its Subsidiaries is in conflict with, or in default or violation of, any of the Company Permits, except for any such conflicts, defaults or violations which, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect.  Since June 30, 2004, neither the Company nor any of its Subsidiaries has received any notification with respect to possible conflicts, defaults or violations of applicable laws, except for notices relating to possible conflicts, defaults or violations, which conflicts, defaults or violations would not have a Material Adverse Effect.

11

s.

Environmental Matters.

(i)

Except as set forth in Schedule 3(s), there are, to the Company’s knowledge, with respect to the Company or any of its Subsidiaries or any predecessor of the Company, no past or present violations of Environmental Laws (as defined below), releases of any material into the environment, actions, activities, circumstances, conditions, events, incidents, or contractual obligations which may give rise to any common law environmental liability or any liability under the Comprehensive Environmental Response, Compensation and Liability Act of 1980 or similar federal, state, local or foreign laws and neither the Company nor any of its Subsidiaries has received any notice with respect to any of the foregoing, nor is any action pending or, to the Company’s knowledge, threatened in connection with any of the foregoing.  The term “Environmental Laws” means all federal, state, local or foreign laws relating to pollution or protection of human health or the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata), including, without limitation, laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants contaminants, or toxic or hazardous substances or wastes (collectively, “Hazardous Materials”) into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands or demand letters, injunctions, judgments, licenses, notices or notice letters, orders, permits, plans or regulations issued, entered, promulgated or approved thereunder.

(ii)

Other than those that are or were stored, used or disposed of in compliance with applicable law, no Hazardous Materials are contained on or about any real property currently owned, leased or used by the Company or any of its Subsidiaries, and no Hazardous Materials were released on or about any real property previously owned, leased or used by the Company or any of its Subsidiaries during the period the property was owned, leased or used by the Company or any of its Subsidiaries, except in the normal course of the Company’s or any of its Subsidiaries’ business.

(iii)

Except as set forth in Schedule 3(s), there are no underground storage tanks on or under any real property owned, leased or used by the Company or any of its Subsidiaries that are not in compliance with applicable law.  

t.

Title to Property.  The Company and its Subsidiaries have good and marketable title in fee simple to all real property and good and marketable title to all personal property owned by them which is material to the business of the Company and its Subsidiaries, in each case free and clear of all liens, encumbrances and defects except such as are described in Schedule 3(t) or such as would not have a Material Adverse Effect.  Any real property and facilities held under lease by the Company and its Subsidiaries are held by them under valid, subsisting and enforceable leases with such exceptions as would not have a Material Adverse Effect.

12

 

u.

Insurance.  The Company and each of its Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as management of the Company believes to be prudent and customary in the businesses in which the Company and its Subsidiaries are engaged.  Neither the Company nor any such Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would not have a Material Adverse Effect.  The Company has provided to Buyer true and correct copies of all policies relating to directors’ and officers’ liability coverage, errors and omissions coverage, and commercial general liability coverage.

v.

Internal Accounting Controls.  The Company and each of its Subsidiaries maintain a system of internal accounting controls sufficient, in the judgment of the Company’s board of directors, to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management’s general or specific authorization and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences.

w.

Foreign Corrupt Practices.  Neither the Company, nor any of its Subsidiaries, nor any director, officer, agent, employee or other person acting on behalf of the Company or any Subsidiary has, in the course of his actions for, or on behalf of, the Company, used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity; made any direct or indirect unlawful payment to any foreign or domestic government official or employee from corporate funds; violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended, or made any bribe, rebate, payoff, influence payment, kickback or other unlawful payment to any foreign or domestic government official or employee.

x.

Solvency.  The Company (after giving effect to the transactions contemplated by this Agreement) is solvent (i.e., its assets have a fair market value in excess of the amount required to pay its probable liabilities on its existing debts as they become absolute and matured) and currently the Company has no information that would lead it to reasonably conclude that the Company would not, after giving effect to the transaction contemplated by this Agreement, have the ability to, nor does it intend to take any action that would impair its ability to, pay its debts from time to time incurred in connection therewith as such debts mature.  The Company did not receive a qualified opinion from its auditors with respect to its most recent fiscal year end and, after giving effect to the transactions contemplated by this Agreement, does not anticipate or know of any basis upon which its auditors might issue a qualified opinion in respect of its current fiscal year.

y.

No Investment Company.  The Company is not, and upon the issuance and sale of the Securities as contemplated by this Agreement will not be an “investment company” required to be registered under the Investment Company Act of 1940 (an “Investment Company”).  The Company is not controlled by an Investment Company.

13

z.

Breach of Representations and Warranties by the Company.  If the Company breaches any of the representations or warranties set forth in this Section 3, and in addition to any other remedies available to the Buyers pursuant to this Agreement, the Company shall pay to the Buyer the Standard Liquidated Damages Amount in cash or in shares of Common Stock at the option of the Company, until such breach is cured.  If the Company elects to pay the Standard Liquidated Damages Amounts in shares of Common Stock, such shares shall be issued at the Conversion Price at the time of payment.

4.

COVENANTS.

a.

Best Efforts.  The parties shall use their best efforts to satisfy timely each of the conditions described in Section 6 and 7 of this Agreement.  

b.

Form D; Blue Sky Laws.  The Company agrees to file a Form D with respect to the Securities as required under Regulation D and to provide a copy thereof to each Buyer promptly after such filing.  The Company shall, on or before the Closing Date, take such action as the Company shall reasonably determine is necessary to qualify the Securities for sale to the Buyers at the applicable closing pursuant to this Agreement under applicable securities or “blue sky” laws of the states of the United States (or to obtain an exemption from such qualification), and shall provide evidence of any such action so taken to each Buyer on or prior to the Closing Date.

c.

Reporting Status; Eligibility to Use Form S-3, SB-2 or Form 

S-1.  The Company’s Common Stock is registered under Section 12(g) of the 1934 Act. The Company represents and warrants that it meets the requirements for the use of Form S-3 (or if the Company is not eligible for the use of Form S-3 as of the Filing Date (as defined in the Registration Rights Agreement), the Company may use the form of registration for which it is eligible at that time) for registration of the sale by the Buyer of the Registrable Securities (as defined in the Registration Rights Agreement).  So long as the Buyer beneficially owns any of the Securities, the Company shall timely file all reports required to be filed with the SEC pursuant to the 1934 Act, and the Company shall not terminate its status as an issuer required to file reports under the 1934 Act even if the 1934 Act or the rules and regulations thereunder would permit such termination.  The Company further agrees to file all reports required to be filed by the Company with the SEC in a timely manner so as to become eligible, and thereafter to maintain its eligibility, for the use of Form S-3.  The Company shall issue a press release describing the material terms of the transaction contemplated hereby as soon as practicable following the Closing Date but in no event more than two (2) business days of the Closing Date, which press release shall be subject to prior review by the Buyers.  The Company agrees that such press release shall not disclose the name of the Buyers unless expressly consented to in writing by the Buyers or unless required by applicable law or regulation, and then only to the extent of such requirement.

14

d.

Use of Proceeds.  The Company shall use the net proceeds from the sale of the Notes and the Warrants in the manner set forth in Schedule 4(d) attached hereto and made a part hereof and shall not, directly or indirectly, use such proceeds for (i) any loan to or investment in any other corporation, partnership, enterprise or other person (except in connection with its currently existing direct or indirect Subsidiaries); (ii) the satisfaction of any portion of the Company’s debt (other than payment of trade payables and accrued expenses in the ordinary course of the Company’s business and consistent with prior past practices), or (iii) the redemption of any Common Stock.

e.

Future Offerings.  Subject to the exceptions described below, the Company will not, without the prior written consent of a majority-in-interest of the Buyers, negotiate or contract with any party to obtain additional equity financing (including debt financing with an equity component) that involves (A) the issuance of Common Stock at a discount to the market price of the Common Stock on the date of issuance (taking into account the value of any warrants or options to acquire Common Stock issued in connection therewith) or (B) the issuance of convertible securities that are convertible into an indeterminate number of shares of Common Stock or (C) the issuance of warrants during the period (the “Lock-up Period”) beginning on the Closing Date and ending on the later of (i) two hundred seventy (270) days from the Closing Date and (ii) one hundred eighty (180) days from the date the Registration Statement (as defined in the Registration Rights Agreement) is declared effective (plus any days in which sales cannot be made thereunder).  In addition, subject to the exceptions described below, the Company will not conduct any equity financing (including debt with an equity component) (“Future Offerings”) during the period beginning on the Closing Date and ending two (2) years after the end of the Lock-up Period unless it shall have first delivered to each Buyer, at least twenty (20) business days prior to the closing of such Future Offering, written notice describing the proposed Future Offering, including the terms and conditions thereof and proposed definitive documentation to be entered into in connection therewith, and providing each Buyer an option during the fifteen (15) day period following delivery of such notice to purchase its pro rata share (based on the ratio that the aggregate principal amount of Notes purchased by it hereunder bears to the aggregate principal amount of Notes purchased hereunder) of the securities being offered in the Future Offering on the same terms as contemplated by such Future Offering (the limitations referred to in this sentence and the preceding sentence are collectively referred to as the “Capital Raising Limitations”).  In the event the terms and conditions of a proposed Future Offering are amended in any respect after delivery of the notice to the Buyers concerning the proposed Future Offering, the Company shall deliver a new notice to each Buyer describing the amended terms and conditions of the proposed Future Offering and each Buyer thereafter shall have an option during the fifteen (15) day period following delivery of such new notice to purchase its pro rata share of the securities being offered on the same terms as contemplated by such proposed Future Offering, as amended.  The foregoing sentence shall apply to successive amendments to the terms and conditions of any proposed Future Offering.  The Capital Raising Limitations shall not apply to any transaction involving (i) issuances of securities in a firm commitment underwritten public offering (excluding a continuous offering pursuant to Rule 415 under the 1933 Act, an equity line of credit or similar financing arrangement) resulting in net proceeds to the Company of in excess of $15,000,000, or (ii) issuances of securities as consideration for a merger, consolidation or purchase of assets, or in connection with any strategic partnership or joint venture (the primary purpose of which is not to raise equity capital), or in connection with the disposition or acquisition of a business, product or license by the Company.  The Capital Raising Limitations also shall not apply to the issuance of securities upon exercise or conversion of the Company’s options, warrants or other convertible securities outstanding as of the date hereof or to the grant of additional options or warrants, or the issuance of additional securities, under any Company stock option or restricted stock plan approved by the shareholders of the Company.  Notwithstanding anything in  this section 4(e) to the contrary, in the event the Company’s Board of Directors decides, in good faith, to enter into a transaction or relationship in which the Company issues shares of Common Stock or other securities of the Company to a person or any entity which is, itself or through its subsidiaries, an operating company in a business synergistic with the business of the Company and in which the Company received benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose business is investing in securities, the Company shall be permitted to do so.

15

 

f.

Expenses.  At the Closing, the Company shall reimburse Buyers for expenses incurred by them in connection with the negotiation, preparation, execution, delivery and performance of this Agreement and the other agreements to be executed in connection herewith (“Documents”), including, without limitation, attorneys’ and consultants’ fees and expenses, transfer agent fees, fees for stock quotation services, fees relating to any amendments or modifications of the Documents or any consents or waivers of provisions in the Documents, fees for the preparation of opinions of counsel, escrow fees, and costs of restructuring the transactions contemplated by the Documents.  When possible, the Company must pay these fees directly, otherwise the Company must make immediate payment for reimbursement to the Buyers for all fees and expenses immediately upon written notice by the Buyer or the submission of an invoice by the Buyer  If the Company fails to reimburse the Buyer in full within three (3) business days of the written notice or submission of invoice by the Buyer, the Company shall pay interest on the total amount of fees to be reimbursed at a rate of 15% per annum.

g.

Financial Information.  The Company agrees to send the following reports to each Buyer until such Buyer transfers, assigns, or sells all of the Securities: (i) within ten (10) days after the filing with the SEC, a copy of its Annual Report on Form 10-KSB its Quarterly Reports on Form 10-QSB and any Current Reports on Form 8-K; (ii) within one (1) day after release, copies of all press releases issued by the Company or any of its Subsidiaries; and (iii) contemporaneously with the making available or giving to the shareholders of the Company, copies of any notices or other information the Company makes available or gives to such shareholders.

16

h.

Authorization and Reservation of Shares.  Subject to Stockholder Approval, the Company shall at all times have authorized, and reserved for the purpose of issuance, a sufficient number of shares of Common Stock to provide for the full conversion or exercise of the outstanding Notes and Warrants and issuance of the Conversion Shares and Warrant Shares in connection therewith (based on the Conversion Price of the Notes or Exercise Price of the Warrants in effect from time to time) and as otherwise required by the Notes.  The Company shall not reduce the number of shares of Common Stock reserved for issuance upon conversion of Notes and exercise of the Warrants without the consent of each Buyer.  The Company shall at all times maintain the number of shares of Common Stock so reserved for issuance at an amount (“Reserved Amount”) equal to no less than two (2) times the number that is then actually issuable upon full conversion of the Notes and Additional Notes and upon exercise of the Warrants and the Additional Warrants (based on the Conversion Price of the Notes or the Exercise Price of the Warrants in effect from time to time).  If at any time the number of shares of Common Stock authorized and reserved for issuance (“Authorized and Reserved Shares”) is below the Reserved Amount, the Company will promptly take all corporate action necessary to authorize and reserve a sufficient number of shares, including, without limitation, calling a special meeting of shareholders to authorize additional shares to meet the Company’s obligations under this Section 4(h), in the case of an insufficient number of authorized shares, obtain shareholder approval of an increase in such authorized number of shares, and voting the management shares of the Company in favor of an increase in the authorized shares of the Company to ensure that the number of authorized shares is sufficient to meet the Reserved Amount.  If the Company fails to obtain such shareholder approval within thirty (30) days following the date on which the number of Reserved Amount exceeds the Authorized and Reserved Shares, the Company shall pay to the Borrower the Standard Liquidated Damages Amount, in cash or in shares of Common Stock at the option of the Buyer.  If the Buyer elects to be paid the Standard Liquidated Damages Amount in shares of Common Stock, such shares shall be issued at the Conversion Price at the time of payment.  In order to ensure that the Company has authorized a sufficient amount of shares to meet the Reserved Amount at all times, the Company must deliver to the Buyer at the end of every month a list detailing (1) the current amount of shares authorized by the Company and reserved for the Buyer; and (2) amount of shares issuable upon conversion of the Notes and upon exercise of the Warrants and as payment of interest accrued on the Notes for one year.  If the Company fails to provide such list within five (5) business days of the end of each month, the Company shall pay the Standard Liquidated Damages Amount, in cash or in shares of Common Stock at the option of the Buyer, until the list is delivered.  If the Buyer elects to be paid the Standard Liquidated Damages Amount in shares of Common Stock, such shares shall be issued at the Conversion Price at the time of payment.

17

i.

Listing.  The Company shall promptly secure the listing or quotation, as the case may be, of the Conversion Shares and Warrant Shares upon each national securities exchange or automated quotation system, if any, upon which shares of Common Stock are then listed or quoted, as the case may be, (subject to official notice of issuance) and, so long as any Buyer owns any of the Securities, shall maintain, so long as any other shares of Common Stock shall be so listed or quoted, as the case may be, such listing or quotation, as the case may be, of all Conversion Shares and Warrant Shares from time to time issuable upon conversion of the Notes or exercise of the Warrants.  The Company will obtain and, so long as any Buyer owns any of the Securities, maintain the listing or quotation, as the case may be, and trading of its Common Stock on the OTCBB or any equivalent replacement exchange, the Nasdaq National Market (“Nasdaq”), the Nasdaq SmallCap Market (“Nasdaq SmallCap”), the New York Stock Exchange (“NYSE”), or the American Stock Exchange (“AMEX”) and will comply in all respects with the Company’s reporting, filing and other obligations under the bylaws or rules of the National Association of Securities Dealers (“NASD”) and such exchanges, as applicable.  The Company shall promptly provide to each Buyer copies of any notices it receives from the OTCBB and any other exchanges or quotation systems on which the Common Stock is then listed or quoted, as the case may be, regarding the continued eligibility of the Common Stock for listing or quotation, as the case may be, on such exchanges and quotation systems.

j.

Corporate Existence.  So long as a Buyer beneficially owns any Notes or Warrants, the Company shall maintain its corporate existence and shall not sell all or substantially all of the Company’s assets, except in the event of a merger or consolidation or sale of all or substantially all of the Company’s assets, where the surviving or successor entity in such transaction (i) assumes the Company’s obligations hereunder and under the agreements and instruments entered into in connection herewith and (ii) is a publicly traded corporation whose Common Stock is listed for trading on the OTCBB, Nasdaq, Nasdaq SmallCap, NYSE or AMEX.

k.

No Integration.  The Company shall not make any offers or sales of any security (other than the Securities) under circumstances that would require registration of the Securities being offered or sold hereunder under the 1933 Act or cause the offering of the Securities to be integrated with any other offering of securities by the Company for the purpose of any stockholder approval provision applicable to the Company or its securities.

18

l.

Subsequent Investment.  The Company and the Buyers agree that, upon the filing by the Company of the Registration Statement to be filed pursuant to the Registration Rights Agreement (the “Filing Date”), the Buyers shall purchase additional Notes (the “Filing Notes”) in the aggregate principal amount of Seven Hundred and Fifty Thousand Dollars ($750,000) and additional warrants (the “Filing Warrants”) to purchase an aggregate of 300,000 shares of Common Stock, for an aggregate purchase price of Seven Hundred and Fifty Thousand Dollars ($750,000), with the closing of such purchase to occur within five (5) days of the Filing Date; provided, however, that the obligation of each Buyer to purchase the Filing Notes and the Filing Warrants is subject to the satisfaction, at or before the closing of such purchase and sale, of the conditions set forth in Section 7.  The Company and the Buyers further agree that, upon the declaration of effectiveness of the Registration Statement to be filed pursuant to the Registration Rights Agreement (the “Effective Date”), the Buyers shall purchase additional notes  (the “Effectiveness Notes” and, collectively with the Filing Notes, the “Additional Notes”) in the aggregate principal amount of One Million Dollars ($1,000,000) and additional warrants (the “Effectiveness Warrants” and, collectively with the Filing Warrants, the “Additional Warrants”) to purchase an aggregate of 400,000 shares of Common Stock, for an aggregate purchase price of One Million Dollars ($1,000,000), with the closing of such purchase to occur within five (5) days of the Effective Date; provided, however, that the obligation of each Buyer to purchase the Additional Notes and the Additional Warrants is subject to the satisfaction, at or before the closing of such purchase and sale, of the conditions set forth in Section 7; and, provided, further, that there shall not have been a Material Adverse Effect as of such effective date.  The terms of the Additional Notes and the Additional Warrants shall be identical to the terms of the Notes and Warrants, as the case may be, to be issued on the Closing Date.  The Common Stock underlying the Additional Notes and the Additional Warrants shall be Registrable Securities (as defined in the Registration Rights Agreement) and shall be included in the Registration Statement to be filed pursuant to the Registration Rights Agreement.

m.

Key Man Insurance.  The Company shall use its best efforts to obtain, on or before five (5) business days from the date hereof, key man life insurance on all key executive employees.

n.

Restriction on Short Sales. The Buyers agree that, so long as any of the Notes remain outstanding, but in no event less than two (2) years from the date hereof, the Buyers will not enter into or effect any “short sales” (as such term is defined in Rule 3b-3 of the 1934 Act) of the Common Stock or hedging transaction which establishes a net short position with respect to the Common Stock.

o.

Breach of Covenants.  If the Company breaches any of the covenants set forth in this Section 4, and in addition to any other remedies available to the Buyers pursuant to this Agreement, the Company shall pay to the Buyers the Standard Liquidated Damages Amount, in cash or in shares of Common Stock at the option of the Company, until such breach is cured.  If the Company elects to pay the Standard Liquidated Damages Amount in shares, such shares shall be issued at the Conversion Price at the time of payment.

19

5.

TRANSFER AGENT INSTRUCTIONS.  The Company shall issue irrevocable instructions to its transfer agent to issue certificates, registered in the name of each Buyer or its nominee, for the Conversion Shares and Warrant Shares in such amounts as specified from time to time by each Buyer to the Company upon conversion of the Notes or exercise of the Warrants in accordance with the terms thereof (the “Irrevocable Transfer Agent Instructions”).  Prior to registration of the Conversion Shares and Warrant Shares under the 1933 Act or the date on which the Conversion Shares and Warrant Shares may be sold pursuant to Rule 144 without any restriction as to the number of Securities as of a particular date that can then be immediately sold, all such certificates shall bear the restrictive legend specified in Section 2(g) of this Agreement.  The Company warrants that no instruction other than the Irrevocable Transfer Agent Instructions referred to in this Section 5, and stop transfer instructions to give effect to Section 2(f) hereof (in the case of the Conversion Shares and Warrant Shares, prior to registration of the Conversion Shares and Warrant Shares under the 1933 Act or the date on which the Conversion Shares and Warrant Shares may be sold pursuant to Rule 144 without any restriction as to the number of Securities as of a particular date that can then be immediately sold), will be given by the Company to its transfer agent and that the Securities shall otherwise be freely transferable on the books and records of the Company as and to the extent provided in this Agreement and the Registration Rights Agreement.  Nothing in this Section shall affect in any way the Buyer’s obligations and agreement set forth in Section 2(g) hereof to comply with all applicable prospectus delivery requirements, if any, upon re-sale of the Securities.  If a Buyer provides the Company with (i) an opinion of counsel in form, substance and scope customary for opinions in comparable transactions, to the effect that a public sale or transfer of such Securities may be made without registration under the 1933 Act and such sale or transfer is effected or (ii) the Buyer provides reasonable assurances that the Securities can be sold pursuant to Rule 144, the Company shall permit the transfer, and, in the case of the Conversion Shares and Warrant Shares, promptly instruct its transfer agent to issue one or more certificates, free from restrictive legend, in such name and in such denominations as specified by such Buyer.  The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Buyers, by vitiating the intent and purpose of the transactions contemplated hereby.  Accordingly, the Company acknowledges that the remedy at law for a breach of its obligations under this Section 5 may be inadequate and agrees, in the event of a breach or threatened breach by the Company of the provisions of this Section, that the Buyers shall be entitled, in addition to all other available remedies, to an injunction restraining any breach and requiring immediate transfer, without the necessity of showing economic loss and without any bond or other security being required.

20

6.

CONDITIONS TO THE COMPANY’S OBLIGATION TO SELL.  The obligation of the Company hereunder to issue and sell the Notes and Warrants to a Buyer at the Closing is subject to the satisfaction, at or before the Closing Date of each of the following conditions thereto, provided that these conditions are for the Company’s sole benefit and may be waived by the Company at any time in its sole discretion:

a.

The applicable Buyer shall have executed this Agreement and the Registration Rights Agreement, and delivered the same to the Company.

b.

The applicable Buyer shall have delivered the Purchase Price in accordance with Section 1(b) above.

c.

The representations and warranties of the applicable Buyer shall be true and correct in all material respects as of the date when made and as of the Closing Date as though made at that time (except for representations and warranties that speak as of a specific date), and the applicable Buyer shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the applicable Buyer at or prior to the Closing Date. 

d.

No litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority over the matters contemplated hereby which prohibits the consummation of any of the transactions contemplated by this Agreement.

7.

CONDITIONS TO EACH BUYER’S OBLIGATION TO PURCHASE.  The obligation of each Buyer hereunder to purchase the Notes and Warrants at the Closing is subject to the satisfaction, at or before the Closing Date of each of the following conditions, provided that these conditions are for such Buyer’s sole benefit and may be waived by such Buyer at any time in its sole discretion:

a.

The Company shall have executed this Agreement and the Registration Rights Agreement, and delivered the same to the Buyer.

b.

The Company shall have delivered to such Buyer duly executed Notes (in such denominations as the Buyer shall request) and Warrants in accordance with Section 1(b) above.

c.

The Irrevocable Transfer Agent Instructions, in form and substance satisfactory to a majority-in-interest of the Buyers, shall have been delivered to and acknowledged in writing by the Company’s Transfer Agent.

21

d.

The representations and warranties of the Company shall be true and correct in all material respects as of the date when made and as of the Closing Date as though made at such time (except for representations and warranties that speak as of a specific date) and the Company shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company at or prior to the Closing Date.  The Buyer shall have received a certificate or certificates, executed by the chief executive officer of the Company, dated as of the Closing Date, to the foregoing effect and as to such other matters as may be reasonably requested by such Buyer including, but not limited to certificates with respect to the Company’s Certificate of Incorporation, By-laws and Board of Directors’ resolutions relating to the transactions contemplated hereby.

e.

No litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority over the matters contemplated hereby which prohibits the consummation of any of the transactions contemplated by this Agreement.

f.

No event shall have occurred which could reasonably be expected to have a Material Adverse Effect on the Company.

g.

The Conversion Shares and Warrant Shares shall have been authorized for quotation on the OTCBB and trading in the Common Stock on the OTCBB  shall not have been suspended by the SEC or the OTCBB.

h.

The Buyer shall have received an opinion of the Company’s counsel, dated as of the Closing Date, in form, scope and substance reasonably satisfactory to the Buyer and in substantially the same form as Exhibit “D” attached hereto.

i.

The Buyer shall have received an officer’s certificate described in Section 3(c) above, dated as of the Closing Date.

22

8.

GOVERNING LAW; MISCELLANEOUS.  

a.

Governing Law.  THIS AGREEMENT SHALL BE ENFORCED, GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK APPLICABLE TO AGREEMENTS MADE AND TO BE PERFORMED ENTIRELY WITHIN SUCH STATE, WITHOUT REGARD TO THE PRINCIPLES OF CONFLICT OF LAWS.  THE PARTIES HERETO HEREBY SUBMIT TO THE EXCLUSIVE JURISDICTION OF THE UNITED STATES FEDERAL COURTS LOCATED IN NEW YORK, NEW YORK WITH RESPECT TO ANY DISPUTE ARISING UNDER THIS AGREEMENT, THE AGREEMENTS ENTERED INTO IN CONNECTION HEREWITH OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. BOTH PARTIES IRREVOCABLY WAIVE THE DEFENSE OF AN INCONVENIENT FORUM TO THE MAINTENANCE OF SUCH SUIT OR PROCEEDING.  BOTH PARTIES FURTHER AGREE THAT SERVICE OF PROCESS UPON A PARTY MAILED BY FIRST CLASS MAIL SHALL BE DEEMED IN EVERY RESPECT EFFECTIVE SERVICE OF PROCESS UPON THE PARTY IN ANY SUCH SUIT OR PROCEEDING.  NOTHING HEREIN SHALL AFFECT EITHER PARTY’S RIGHT TO SERVE PROCESS IN ANY OTHER MANNER PERMITTED BY LAW.  BOTH PARTIES AGREE THAT A FINAL NON-APPEALABLE JUDGMENT IN ANY SUCH SUIT OR PROCEEDING SHALL BE CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON SUCH JUDGMENT OR IN ANY OTHER LAWFUL MANNER.  THE PARTY WHICH DOES NOT PREVAIL IN ANY DISPUTE ARISING UNDER THIS AGREEMENT SHALL BE RESPONSIBLE FOR ALL FEES AND EXPENSES, INCLUDING ATTORNEYS’ FEES, INCURRED BY THE PREVAILING PARTY IN CONNECTION WITH SUCH DISPUTE.

b.

Counterparts; Signatures by Facsimile.  This Agreement may be executed in one or more counterparts, each of which shall be deemed an original but all of which shall constitute one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party.  This Agreement, once executed by a party, may be delivered to the other party hereto by facsimile transmission of a copy of this Agreement bearing the signature of the party so delivering this Agreement.

c.

Headings.  The headings of this Agreement are for convenience of reference only and shall not form part of, or affect the interpretation of, this Agreement.  

d.

Severability.  In the event that any provision of this Agreement is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law.  Any provision hereof which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision hereof.

23

e.

Entire Agreement; Amendments.  This Agreement and the instruments referenced herein contain the entire understanding of the parties with respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither the Company nor the Buyer makes any representation, warranty, covenant or undertaking with respect to such matters.  No provision of this Agreement may be waived or amended other than by an instrument in writing signed by the party to be charged with enforcement.  

f.

Notices.  Any notices required or permitted to be given under the terms of this Agreement shall be sent by certified or registered mail (return receipt requested) or delivered personally or by courier (including a recognized overnight delivery service) or by facsimile and shall be effective five days after being placed in the mail, if mailed by regular United States mail, or upon receipt, if delivered personally or by courier (including a recognized overnight delivery service) or by facsimile, in each case addressed to a party.  The addresses for such communications shall be:

If to the Company:

INFE, Human Resources, Inc.

67 Wall Street, 22nd Floor

New York, NY 10005

Attention: Chief Executive Officer 

Telephone:

(212) 859-3466

Facsimile:

With a copy to:

Laura Anthony, Esq.

330 Clemants Street, #217

West Palm Beach, FL 33401

Attention:  Laura Anthony, Esq.

Telephone:  (561) 514-0936

Facsimile:   (561) 514-0832

If to a Buyer:  To the address set forth immediately below such Buyer’s name on the signature pages hereto.

With copy to:

Ballard Spahr Andrews & Ingersoll, LLP

1735 Market Street

51st Floor

Philadelphia, Pennsylvania  19103

Attention:  Gerald J. Guarcini, Esq.

Telephone:  215-864-8625

Facsimile:  215-864-8999

24

Each party shall provide notice to the other party of any change in address.

g.

Successors and Assigns.  This Agreement shall be binding upon and inure to the benefit of the parties and their successors and assigns.  Neither the Company nor any Buyer shall assign this Agreement or any rights or obligations hereunder without the prior written consent of the other.  Notwithstanding the foregoing, subject to Section 2(f), any Buyer may assign its rights hereunder to any person that purchases Securities in a private transaction from a Buyer or to any of its “affiliates,” as that term is defined under the 1934 Act, without the consent of the Company.

h.

Third Party Beneficiaries.  This Agreement is intended for the benefit of the parties hereto and their respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person.

i.

Survival.  The representations and warranties of the Company and the agreements and covenants set forth in Sections 3, 4, 5 and 8 shall survive the closing hereunder notwithstanding any due diligence investigation conducted by or on behalf of the Buyers.  The Company agrees to indemnify and hold harmless each of the Buyers and all their officers, directors, employees and agents for loss or damage arising as a result of or related to any breach or alleged breach by the Company of any of its representations, warranties and covenants set forth in Sections 3 and 4 hereof or any of its covenants and obligations under this Agreement or the Registration Rights Agreement, including advancement of expenses as they are incurred.

j.

Publicity.  The Company and each of the Buyers shall have the right to review a reasonable period of time before issuance of any press releases, SEC, OTCBB or NASD filings, or any other public statements with respect to the transactions contemplated hereby; provided, however, that the Company shall be entitled, without the prior approval of each of the Buyers, to make any press release or SEC, OTCBB (or other applicable trading market) or NASD filings with respect to such transactions as is required by applicable law and regulations (although each of the Buyers shall be consulted by the Company in connection with any such press release prior to its release and shall be provided with a copy thereof and be given an opportunity to comment thereon).

k.

Further Assurances.  Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

l.

No Strict Construction.  The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party.

25

m.

Remedies.  The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Buyers by vitiating the intent and purpose of the transaction contemplated hereby.  Accordingly, the Company acknowledges that the remedy at law for a breach of its obligations under this Agreement will be inadequate and agrees, in the event of a breach or threatened breach by the Company of the provisions of this Agreement, that the Buyers shall be entitled, in addition to all other available remedies at law or in equity, and in addition to the penalties assessable herein, to an injunction or injunctions restraining, preventing or curing any breach of this Agreement and to enforce specifically the terms and provisions hereof, without the necessity of showing economic loss and without any bond or other security being required.

26

IN WITNESS WHEREOF, the undersigned Buyers and the Company have caused this Agreement to be duly executed as of the date first above written.

INFE, HUMAN RESOURCES, INC.

________________________________

Arthur Viola

Chief Executive Officer 

AJW PARTNERS, LLC

By:  SMS Group, LLC

______________________________________

Corey S. Ribotsky

Manager

RESIDENCE:  Delaware

ADDRESS:

1044 Northern Boulevard

Suite 302

Roslyn, New York 11576

Facsimile:  (516) 739-7115

Telephone:  (516) 739-7110

AGGREGATE SUBSCRIPTION AMOUNT:

Aggregate Principal Amount of Notes:

$________

Number of Warrants:

  ________

Aggregate Purchase Price:

$________

 

27

AJW OFFSHORE, LTD.

By:  First Street Manager II, LLC

______________________________________

Corey S. Ribotsky 

Manager

RESIDENCE:

    Cayman Islands

ADDRESS:

AJW Offshore, Ltd.

P.O. Box 32021 SMB

Grand Cayman, Cayman Island, B.W.I. 

AGGREGATE SUBSCRIPTION AMOUNT:

Aggregate Principal Amount of Notes:

$_______

Number of Warrants:

_______

Aggregate Purchase Price:

$_______

 

28

AJW QUALIFIED PARTNERS, LLC

By:  AJW Manager, LLC

____________________________________

Corey S. Ribotsky 

Manager

RESIDENCE:

    New York

ADDRESS:

1044 Northern Boulevard

Suite 302

Roslyn, New York 11576

Facsimile:

(516) 739-7115

Telephone:

(516) 739-7110

AGGREGATE SUBSCRIPTION AMOUNT:

Aggregate Principal Amount of Notes:

$________

Number of Warrants:

________

Aggregate Purchase Price:

$________

  

29

NEW MILLENNIUM CAPITAL PARTNERS II, LLC 

By:  First Street Manager II, LLP

____________________________________

Corey S. Ribotsky 

Manager

RESIDENCE:

    New York

ADDRESS:

1044 Northern Boulevard

Suite 302

Roslyn, New York 11576

Facsimile:

(516) 739-7115

Telephone:

(516) 739-7110

AGGREGATE SUBSCRIPTION AMOUNT:

Aggregate Principal Amount of Notes:

$______

Number of Warrants:

______

Aggregate Purchase Price:

$______

  

30

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00106-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00106-of-00352.parquet"}]]